drugset / Trial / NCT06431607
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).
Timeline
- Start
- 2024-05-23
- Primary completion
- 2024-12-27
- Completion
- 2025-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F2G22B/DL001Z | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | F2H23A/DL001Z-NH | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | F2H23B/DL001Z-NH | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | F2H23D/DL001Z-NH | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | F2H23G/DL001Z | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | F2H23H/DL001Z | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | FDQ23A-NH | Vaccine | — | Intramuscular |
| Subject | Flu D-TIV | Vaccine | — | Intramuscular |
| Subject | Fluzone HD Quadrivalent | Vaccine | — | Intramuscular |
| Subject | GSK5800544A | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | Influenza Virus Vaccine | Vaccine | — | Intramuscular |